L. Mezzabotta

1.0k total citations
24 papers, 544 citations indexed

About

L. Mezzabotta is a scholar working on Epidemiology, Surgery and Hepatology. According to data from OpenAlex, L. Mezzabotta has authored 24 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 9 papers in Surgery and 9 papers in Hepatology. Recurrent topics in L. Mezzabotta's work include Liver Disease Diagnosis and Treatment (13 papers), Pancreatitis Pathology and Treatment (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). L. Mezzabotta is often cited by papers focused on Liver Disease Diagnosis and Treatment (13 papers), Pancreatitis Pathology and Treatment (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). L. Mezzabotta collaborates with scholars based in Italy, Lebanon and Australia. L. Mezzabotta's co-authors include Elisabetta Bugianesi, Ester Vanni, Andrea Marengo, Chiara Rosso, Mario Rizzetto, Daniela Cabibi, Antonio Craxı̀, Salvatore Petta, Calogero Cammà and Roberto Gambino and has published in prestigious journals such as Hepatology, International Journal of Molecular Sciences and Journal of Hepatology.

In The Last Decade

L. Mezzabotta

21 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Mezzabotta Italy 11 379 195 173 145 85 24 544
Snow Yunni Lin Singapore 9 309 0.8× 123 0.6× 117 0.7× 132 0.9× 44 0.5× 18 441
F.J. Carrilho Brazil 7 276 0.7× 288 1.5× 163 0.9× 75 0.5× 60 0.7× 21 521
Takumi Akiyama Japan 12 272 0.7× 249 1.3× 163 0.9× 54 0.4× 119 1.4× 25 534
Bart J. Verwer Netherlands 7 416 1.1× 345 1.8× 141 0.8× 87 0.6× 34 0.4× 9 533
A Beilfuss Germany 9 325 0.9× 106 0.5× 107 0.6× 93 0.6× 93 1.1× 11 493
John H. Helzberg United States 13 221 0.6× 205 1.1× 200 1.2× 39 0.3× 63 0.7× 32 579
Cameron T. Locklear United States 6 354 0.9× 221 1.1× 55 0.3× 135 0.9× 51 0.6× 7 503
Koji Shiota Japan 6 300 0.8× 277 1.4× 127 0.7× 54 0.4× 54 0.6× 11 476
S. Lombardini Italy 9 367 1.0× 117 0.6× 95 0.5× 207 1.4× 20 0.2× 11 542
Hisao Ezaki Japan 10 267 0.7× 140 0.7× 110 0.6× 77 0.5× 29 0.3× 12 439

Countries citing papers authored by L. Mezzabotta

Since Specialization
Citations

This map shows the geographic impact of L. Mezzabotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Mezzabotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Mezzabotta more than expected).

Fields of papers citing papers by L. Mezzabotta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Mezzabotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Mezzabotta. The network helps show where L. Mezzabotta may publish in the future.

Co-authorship network of co-authors of L. Mezzabotta

This figure shows the co-authorship network connecting the top 25 collaborators of L. Mezzabotta. A scholar is included among the top collaborators of L. Mezzabotta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Mezzabotta. L. Mezzabotta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosso, Chiara, Gian Paolo Caviglia, Maria Lorena Abate, et al.. (2015). Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Digestive and Liver Disease. 48(1). 55–61. 24 indexed citations
2.
3.
Risso, À., Carlo Alessandria, L. Mezzabotta, et al.. (2015). Adrenal function and microbial DNA in noninfected cirrhotic patients with ascites: Relationship and effect on survival. Digestive and Liver Disease. 47(8). 702–708. 4 indexed citations
4.
Rosso, Chiara, L. Mezzabotta, Melania Gaggini, et al.. (2015). Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 63(1). 107–116. 57 indexed citations
5.
6.
Vanni, Ester, Andrea Marengo, L. Mezzabotta, & Elisabetta Bugianesi. (2015). Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. Seminars in Liver Disease. 35(3). 236–249. 64 indexed citations
7.
Petta, Salvatore, Ester Vanni, Elisabetta Bugianesi, et al.. (2014). The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver International. 35(5). 1566–1573. 102 indexed citations
8.
Vanni, Ester, Chiara Rosso, L. Mezzabotta, et al.. (2014). Matabolomic analysis identifies new biomarkers of liver damage in NAFLD. 1 indexed citations
9.
Gastaldelli, Amalia, Melania Gaggini, L. Mezzabotta, et al.. (2013). Alteration in lipid metabolism after an oral fat load in subjects with NAFLD.. Diabetologia. 56. 2 indexed citations
10.
Bruno, Mauro, L. Mezzabotta, P. Carucci, et al.. (2013). Unexplained Common Bile Duct Dilatation With Normal Serum Liver Enzymes. Journal of Clinical Gastroenterology. 48(8). e67–e70. 28 indexed citations
11.
Angulo, Paul, Jacob George, Christopher P. Day, et al.. (2013). Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 12(7). 1163–1169.e1. 46 indexed citations
12.
Alessandria, Carlo, Chiara Elia, L. Mezzabotta, et al.. (2011). Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Digestive and Liver Disease. 43(11). 881–6. 41 indexed citations
13.
Elia, Celeste C., Carlo Alessandria, L. Mezzabotta, et al.. (2011). 106 ADRENAL DYSFUNCTION IN NONSEPTIC CIRRHOTIC PATIENTS WITH ASCITES: IMPACT ON SURVIVAL. Journal of Hepatology. 54. S48–S48.
14.
Risso, À., Carlo Alessandria, Celeste C. Elia, et al.. (2011). OC-30 Adrenal dysfunction in nonseptic cirrhotic patients with ascites: Impact on survival. Digestive and Liver Disease. 43. S74–S75. 10 indexed citations
15.
Bruno, Mauro, Martino Bosco, P. Carucci, et al.. (2009). Preliminary experience with a new cytology brush in EUS-guided FNA. Gastrointestinal Endoscopy. 70(6). 1220–1224. 31 indexed citations
16.
Angelis, C.G. De, Donatella Pacchioni, A. Barreca, et al.. (2009). EUS-GUIDED CYTOLOGIC DIAGNOSIS OF PANCREATIC ENDOCRINE TUMORS (PETS): IMPACT OF ON-SITE CYTOPATHOLOGICAL ASSESSMENT. Digestive and Liver Disease. 41. S63–S63. 1 indexed citations
17.
Bruno, Mauro, P. Carucci, Alessandro Repici, et al.. (2009). The Natural History of Gastrointestinal Subepithelial Tumors Arising From Muscularis Propria. Journal of Clinical Gastroenterology. 43(9). 821–825. 22 indexed citations
18.
Alessandria, Carlo, L. Mezzabotta, W. Debernardi‐Venon, et al.. (2009). Relative adrenal insufficiency in cirrhosis: Relevance in patients with ascites and treatment with hydrocortisone in refractory ascites. Digestive and Liver Disease. 41(3). A13–A13. 3 indexed citations
19.
Angelis, C.G. De, P. Carucci, Alessandro Repici, et al.. (2009). THE CHALLENGING DIFFERENTIAL DIAGNOSIS OF SOLID PANCREATIC MASSES: IS THERE A ROLE FOR CONTRAST-ENHANCED EUS (CE-EUS)?. Digestive and Liver Disease. 41. S61–S62. 1 indexed citations
20.
Angelis, Claudio De, Alessandro Repici, P. Carucci, et al.. (2007). Pancreatic cancer imaging: the new role of endoscopic ultrasound.. PubMed. 8(1 Suppl). 85–97. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Snow Yunni Lin Breakdown of academic impact, for papers by F.J. Carrilho Breakdown of academic impact, for papers by Takumi Akiyama Breakdown of academic impact, for papers by Bart J. Verwer Breakdown of academic impact, for papers by A Beilfuss Breakdown of academic impact, for papers by John H. Helzberg Breakdown of academic impact, for papers by Cameron T. Locklear Breakdown of academic impact, for papers by Koji Shiota Breakdown of academic impact, for papers by S. Lombardini Breakdown of academic impact, for papers by Hisao Ezaki
Rankless by CCL
2026